The role of the human papilloma virus in the development of potentially malignant diseases and squamous cell carcinomas of the oral mucosa

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

The prevalence of HPV in potentially malignant diseases of the oral cavity is 22.5%. Different types of HPV are characterized by genotypic variations in the DNA base sequences E6 and E7. It is these genotypic differences that make it possible to divide the oncogenic phenotype of the virus into types of high and low cancer risk. There are local and general risk factors for HPV infection. Local risk factors include poor oral hygiene, the use of complete dentures in combination with old age. A significant correlation between oral hygiene and viral load has been confirmed. This review presents the possible role of human papillomavirus (HPV) in the development of potentially malignant diseases and squamous cell carcinomas of the oral cavity. The epidemiology, risk factors and mechanisms of human papillomavirus infection development are given. Clinical and morphological differences between HPV-positive and HPV-negative forms of oral cancer are considered. The issues of HPV infection prevention and the pathogenetic therapy development of this disease are reviewed. Literature search was carried out in search engines Medline, Elibrary, Scopus, PubMed, The Cochrane Library, RSCI.

作者简介

Dmitry Mikhalev

Siberian State Medical University

编辑信件的主要联系方式.
Email: dm199412@gmail.com
ORCID iD: 0000-0002-0647-3576

Postgraduate Student

俄罗斯联邦, Tomsk

Olga Baydik

Siberian State Medical University

Email: olgabajdik@yandex.ru
ORCID iD: 0000-0002-4748-4175

MD, Dr. Sci. (Med.), Professor

俄罗斯联邦, Tomsk

Marat Mukhamedov

Siberian State Medical University; Cancer Research Institute of Tomsk National Research Medical Center of Russian Academy of Science

Email: muhamedov@oncology.tomsk.ru
ORCID iD: 0000-0003-1555-050X

MD, Dr. Sci. (Med.)

俄罗斯联邦, Tomsk; Tomsk

Georgy Aleksandrov

Siberian State Medical University

Email: go.alexandrov@gmail.com
ORCID iD: 0000-0002-1531-1528
俄罗斯联邦, Tomsk

参考

  1. Serrano B, Brotons M, Bosch FX, Bruni L. Epidemiology and burden of HPV-related disease. Best Pract Res Clin Obstet Gynaecol. 2018;47:14–26. doi: 10.1016/j.bpobgyn.2017.08.006
  2. Sritippho T, Chotjumlong P, Iamaroon A. Roles of Human Papillomaviruses and p16 in Oral Cancer. Asian Pac J Cancer Prev. 2015;16(15):6193–6200. doi: 10.7314/apjcp.2015.16.15.6193
  3. De la Cour CD, Sperling CD, Belmonte F, et al. Human papillomavirus prevalence in oral potentially malignant disorders: Systematic review and meta-analysis. Oral Dis. 2021;27(3):431–438. doi: 10.1111/odi.13322
  4. Boda D, Docea AO, Calina D, et al. Human papilloma virus: Apprehending the link with carcinogenesis and unveiling new research avenues (Review). Int J Oncol. 2018;52(3):637–655. doi: 10.3892/ijo.2018.4256
  5. Graham SV. The human papillomavirus replication cycle, and its links to cancer progression: a comprehensive review. Clin Sci (Lond). 2017;131(17):2201–2221. doi: 10.1042/CS20160786
  6. Dalla Torre D, Burtscher D, Sölder E, et al. The correlation between the quality of oral hygiene and oral HPV infection in adults: a prospective cross-sectional study. Clin Oral Investig. 2019;23(1):179–185. doi: 10.1007/s00784-018-2425-y
  7. Sun CX, Bennett N, Tran P, et al. A Pilot Study into the Association between Oral Health Status and Human Papillomavirus-16 Infection. Diagnostics (Basel). 2017;7(1):11. doi: 10.3390/diagnostics7010011
  8. Christensen ND. HPV disease transmission protection and control. Microb Cell. 2016;3(9):476–490. doi: 10.15698/mic2016.09.530
  9. Bui TC, Tran LT, Markham CM, et al. Self-reported oral health, oral hygiene, and oral HPV infection in at-risk women in Ho Chi Minh City, Vietnam. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015;120(1):34–42. doi: 10.1016/j.oooo.2015.04.004
  10. D’Souza G, McNeel TS, Fakhry C. Understanding personal risk of oropharyngeal cancer: risk-groups for oncogenic oral HPV infection and oropharyngeal cancer. Ann Oncol. 2017;28(12):3065–3069. doi: 10.1093/annonc/mdx535
  11. Bui TC, Tran LT, Thai TN, et al. Prevalence of and Risk Factors for Oral Human Papillomavirus Infection with Multiple Genotypes in the United States. Sex Transm Dis. 2017;44(3):166–172. doi: 10.1097/OLQ.0000000000000563
  12. Shah A, Malik A, Garg A, et al. Oral sex and human papilloma virus-related head and neck squamous cell cancer: a review of the literature. Postgrad Med J. 2017;93(1105):704–709. doi: 10.1136/postgradmedj-2016-134603
  13. Candotto V, Lauritano D, Nardone M, et al. HPV infection in the oral cavity: epidemiology, clinical manifestations and relationship with oral cancer. Oral Implantol (Rome). 2017;10(3):209–220. doi: 10.11138/orl/2017.10.3.209
  14. Giuliani E, Rollo F, Donà MG, Garbuglia AR. Human Papillomavirus Oral Infection: Review of Methodological Aspects and Epidemiology. Pathogens. 2021;10(11):1411. doi: 10.3390/pathogens10111411
  15. Vergori A, Garbuglia AR, Piselli P, et al. Oral human Papillomavirus DNA detection in HIV-positive men: prevalence, predictors, and co-occurrence at anal site. BMC Infect Dis. 2018;18(1):25. doi: 10.1186/s12879-017-2937-0
  16. Sano D, Oridate N. The molecular mechanism of human papillomavirus-induced carcinogenesis in head and neck squamous cell carcinoma. Int J Clin Oncol. 2016;21(5):819–826. doi: 10.1007/s10147-016-1005-x
  17. Bzhalava Z, Arroyo Mühr LS, Dillner J. Transcription of human papillomavirus oncogenes in head and neck squamous cell carcinomas. Vaccine. 2020;38(25):4066–4070. doi: 10.1016/j.vaccine.2020.04.049
  18. Vats A, Trejo-Cerro O, Thomas M, Banks L. Human papillomavirus E6 and E7: What remains? Tumour Virus Res. 2021;11:200213. doi: 10.1016/j.tvr.2021.200213
  19. Kulaberoglu Y, Gundogdu R, Hergovich A. The role of p53/p21/p16 in DNA-damage signaling and DNA repair. In: Kovalchuk I, Kovalchuk O, editors. Genome Stability. From Virus to Human Application. Academic Press; 2016. P:243–256. doi: 10.1016/b978-0-12-803309-8.00015-x
  20. Kolluru S, Momoh R, Lin L, et al. Identification of potential binding pocket on viral oncoprotein HPV16 E6: a promising anti-cancer target for small molecule drug discovery. BMC Mol Cell Biol. 2019;20(1):30. doi: 10.1186/s12860-019-0214-3
  21. Taberna M, Mena M, Pavón MA, et al. Human papillomavirus-related oropharyngeal cancer. Ann Oncol. 2017;28(10):2386–2398. doi: 10.1093/annonc/mdx304
  22. Arians N, Prigge ES, Nachtigall T, et al. Overexpression of p16INK4a Serves as Prognostic Marker in Squamous Cell Vulvar Cancer Patients Treated With Radiotherapy Irrespective of HPV-Status. Front Oncol. 2019;9:891. doi: 10.3389/fonc.2019.00891
  23. Prigge ES, Arbyn M, von Knebel Doeberitz M, Reuschenbach M. Diagnostic accuracy of p16INK4a immunohistochemistry in oropharyngeal squamous cell carcinomas: A systematic review and meta-analysis. Int J Cancer. 2017;140(5):1186–1198. doi: 10.1002/ijc.30516
  24. Arizmendi-Izazaga A, Navarro-Tito N, Jiménez-Wences H, et al. Metabolic Reprogramming in Cancer: Role of HPV 16 Variants. Pathogens. 2021;10(3):347. doi: 10.3390/pathogens10030347
  25. Bano N, Yadav M, Mohania D, Das BC. The role of NF-κB and miRNA in oral cancer and cancer stem cells with or without HPV16 infection. PLoS One. 2018;13(10):e0205518. doi: 10.1371/journal.pone.0205518. Retraction in: PLoS One. 2020;15(11):e0242853.
  26. Sameera A, Kotikalpudi R, Patel RK, et al. Molecular detection of human papillomavirus DNA in oral lichen planus patients. J Clin Diagn Res. 2019;13(1):ZC20–ZC24. doi: 10.7860/JCDR/2019/32397.12466
  27. Sushma C, Birur NP, Suresh A, et al. Detection of HPV16 in tissues of oral leukoplakia by polymerase chain reaction and p16 immunohistochemistry: A prospective study. Transl Res. 2017. doi: 10.1177/2057178X17713880
  28. Shang Q, Peng J, Zhou Y, et al. Association of Human Papillomavirus With Oral Lichen Planus and Oral Leukoplakia: A Meta-analysis. J Evid Based Dent Pract. 2020;20(4):101485. doi: 10.1016/j.jebdp.2020.101485
  29. Steinbach A, Riemer AB. Immune evasion mechanisms of human papillomavirus: An update. Int J Cancer. 2018;142(2):224–229. doi: 10.1002/ijc.31027
  30. Westrich JA, Warren CJ, Pyeon D. Evasion of host immune defenses by human papillomavirus. Virus Res. 2017;231:21–33. doi: 10.1016/j.virusres.2016.11.023
  31. Melo BAC, Vilar LG, Oliveira NR, et al. Human papillomavirus infection and oral squamous cell carcinoma — a systematic review. Braz J Otorhinolaryngol. 2021;87(3):346–352. doi: 10.1016/j.bjorl.2020.10.017
  32. Gillison ML, Akagi K, Xiao W, et al. Human papillomavirus and the landscape of secondary genetic alterations in oral cancers. Genome Res. 2019;29(1):1–17. doi: 10.1101/gr.241141.118
  33. Berteșteanu ȘVG, Grigore R, Nicolaescu A, Cojocărița-Condeescu M. HPV-Positive Oral Squamous Cell Carcinoma. In: Rajamanickam R., editor. Human Papillomavirus. IntechOpen; 2020. doi: 10.5772/intechopen.90954
  34. Dvorayninova OYu, Choynzonov EL, Litvyakov NV. The clinical aspects of HPV-positive cancer of the oral cavity and oropharynx. Vestnik Oto-Rino-Laringologii. 2016;81(1):72–77. (In Russ). doi: 10.17116/otorino201681172-77
  35. Mamo L, Epstein S. The new sexual politics of cancer: Oncoviruses, disease prevention, and sexual health promotion. BioSocieties. 2017;2:367–391. doi: 10.1057/biosoc.2016.10
  36. Yousefi Z, Aria H, Ghaedrahmati F, et al. An Update on Human Papilloma Virus Vaccines: History, Types, Protection, and Efficacy. Front Immunol. 2022;12:805695. doi: 10.3389/fimmu.2021.805695
  37. Toh ZQ, Kosasih J, Russell FM, et al. Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus. Infect Drug Resist. 2019;12:1951–1967. doi: 10.2147/IDR.S178381
  38. Chaturvedi AK, Graubard BI, Broutian T, et al. Effect of Prophylactic Human Papillomavirus (HPV) Vaccination on Oral HPV Infections Among Young Adults in the United States. J Clin Oncol. 2018;36(3):262–267. doi: 10.1200/JCO.2017.75.0141
  39. Domingos-Pereira S, Galliverti G, Hanahan D, Nardelli-Haefliger D. Carboplatin/paclitaxel, E7-vaccination and intravaginal CpG as tri-therapy towards efficient regression of genital HPV16 tumors. J Immunother Cancer. 2019;7(1):122. doi: 10.1186/s40425-019-0593-1
  40. Yete S, D’Souza W, Saranath D. High-risk human papillomavirus in oral cancer: clinical implications. Oncology. 2018;94(3):133–141. doi: 10.1159/000485322
  41. Yang MC, Yang A, Qiu J, et al. Buccal injection of synthetic HPV long peptide vaccine induces local and systemic antigen-specific CD8+ T-cell immune responses and antitumor effects without adjuvant. Cell Biosci. 2016;6:17. doi: 10.1186/s13578-016-0083-9

版权所有 © Mikhalev D.E., Baydik O.D., Mukhamedov M.R., Aleksandrov G.O., 2022

Creative Commons License
此作品已接受知识共享署名-非商业性使用-禁止演绎 4.0国际许可协议的许可。
 


##common.cookie##